Yoanna Skrobik. The Lancet, Volume 376, Issue 9755, Pages 1805 – 1807, 27 November 2010
Rivastigmine, a cholinesterase inhibitor, has been used to treat delirium in elderly patients with stroke. 1 A biologically plausible premise—that impaired cholinergic transmission might either cause or worsen delirium—led to a randomised, placebo-controlled, double-blind trial by Maarten van Eijk and colleagues 2 in The Lancet in which they added rivastigmine or placebo to usual treatment of patients in intensive care.
The trial was halted at 104 patients by the drug safety and monitoring board (DSMB …
Weblink here